Farmacocinética poblacional de doxorubicina aplicada a la personalización de su dosificación en pacientes oncológicos
Authors:
- A. Ramón-LópezARA. Ramón-López
- M.A J. DuartMDM.A J. Duart
- J.J. Pérez-RuixoJPJ.J. Pérez-Ruixo
- B. ValenzuelaBVB. Valenzuela
Open Access
- 1 July 2012
- journal article
- abstracts
- Published by Elsevier in Farmacia Hospitalaria
- Vol. 36 (4) , 282-291
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Doxorubicin in Lymphoma: Association Between Pharmacokinetic Variability and Clinical ResponseTherapeutic Drug Monitoring, 2010
- Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicityPharmacogenetics and Genomics, 2008
- Inhibition of Polymorphic Human Carbonyl Reductase 1 (CBR1) by the Cardioprotectant Flavonoid 7-monohydroxyethyl Rutoside (monoHER)Pharmaceutical Research, 2008
- Population Pharmacokinetics and Pharmacodynamics of Doxorubicin and Cyclophosphamide in Breast Cancer PatientsClinical Pharmacokinetics, 2007
- Pharmacokinetic-Pharmacodynamic Relationships of the Anthracycline Anticancer DrugsClinical Pharmacokinetics, 2002
- A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicinBiochemical Pharmacology, 1999
- Doxorubicin pharmacokinetics: the effect of abnormal liver biochemistry testsCancer Chemotherapy and Pharmacology, 1998
- Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistryCancer Chemotherapy and Pharmacology, 1995
- Some suggestions for measuring predictive performanceJournal of Pharmacokinetics and Biopharmaceutics, 1981
- Estimation of population characteristics of pharmacokinetic parameters from routine clinical dataJournal of Pharmacokinetics and Biopharmaceutics, 1977